TWST — Twist Bioscience Corporation stock price, charts and financials

QT80Twist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ: TWST) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
101.06
+9.51+10.39%
OverviewShort InterestFilings
TWSTQT80Twist Bioscience Corporation·NASDAQ
101.06+10.39%
Earnings
Up 10.4% — Reported earnings — EPS missed by 20%, revenue beat by 2%.
High confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BLLN-0.92%$137.32SHC+0.73%$17.99RDNT+4.74%$66.80QGEN+2.25%$42.33VCYT-3.17%$44.85CRL-0.71%$230.87NEOG-1.16%$11.90ICLR-3.15%$158.41
Snapshot
Index-P/E-EPS (ttm)-1.33Insider Own4.02%Shs Outstand62.27MPerf Week1.42%
Market Cap5.70BForward P/E-EPS next Y-1.40Insider Trans-16.29%Shs Float59.69MPerf Month-10.46%
Enterprise Value5.67BPEG-EPS next Q-Inst Own126.08%Short Float23.65%Perf Quarter56.63%
Income-82.09MP/S13.92EPS this Y-57.71%Inst Trans-Short Ratio8.09Perf Half Y120.18%
Sales409.48MP/B12.41EPS next Y33.31%ROA-12.02%Short Interest14.12MPerf YTD188.62%
Book/sh-P/C-EPS next 5Y-ROE-17.46%52W High116.43 -13.20%Perf Year163.60%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-24.50%52W Low25.72 292.92%Perf 3Y244.56%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.72% 33.17%Gross Margin52.07%Volatility7.47% 7.14%Perf 5Y-21.98%
Dividend TTM-EV/Sales13.86EPS Y/Y TTM63.06%Oper. Margin-33.90%ATR (14)6.43Perf 10Y-
Dividend Ex-Date-Quick Ratio2.42Sales Y/Y TTM30.99%Profit Margin-19.85%RSI (14)53.19Recom2.29
Dividend Gr. 3/5Y-Current Ratio2.70EPS Q/Q5.66%SMA200.12%Beta2.09Target Price95.78
Payout0.00%Debt/Eq0.21Sales Q/Q19.35%SMA509.63%Rel Volume0.86Prev Close91.55
Employees979LT Debt/Eq0.26EarningsAug 03SMA20074.11%Avg Volume1.74MPrice101.06
IPO DateOct 31, 2018Option/ShortYes / YesEPS/Sales Surpr.-19.72% 1.78%Net Debt/EBITDA0.48Volume1,494,156Change10.39%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-16-26ReiteratedLeerink PartnersOutperform$80 → $110
Jul-14-26ReiteratedCanaccord GenuityBuy$90 → $120
Jul-06-26DowngradeEvercore ISI GroupOutperform → In Line$52 → $102
Jun-29-26ReiteratedGuggenheimBuy$60 → $107
Jun-24-26ReiteratedBarclaysOverweight$65 → $95
Jun-15-26ReiteratedCowen & Co.Outperform$68 → $89
Jun-15-26InitiatedCanaccordBuy$90
Jun-15-26ReiteratedUBS$89
Jun-11-26ReiteratedPiper SandlerOverweight$85
May-22-26ReiteratedLeerink PartnersOutperform$80
Latest News
Today
Today02:39PM
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcriptseekingalpha.com
11:03AM
Twist Bioscience Q3 Earnings Call Highlightsmarketbeat.com
09:26AM
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimateszacks.com
Jul-21-26
Jul-21-2603:07AM
Allspring Global Investments Holdings LLC Purchases Shares of 455,446 Twist Bioscience Corporation $TWSTdefenseworld.net
Jul-19-26
Jul-19-2610:53AM
Thrivent Small Cap Growth Fund Q2 2026 Portfolio ReviewSeekingAlpha
Jul-15-26
Jul-15-2601:56PM
Artisan Mid Cap Fund Q2 2026 Performance ReviewSeekingAlpha
08:00AM
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026businesswire.com
Jul-08-26
Jul-08-2606:49AM
Twist Bioscience: An AI And Rate Cut Play Dressed In A Lab CoatSeekingAlpha
Jul-06-26
Jul-06-2608:27AM
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102Benzinga
Jun-29-26
Jun-29-2605:20PM
Biotech Is The Rate Cut Trade In DisguiseSeekingAlpha
Jun-26-26
Jun-26-2602:20PM
The Disinflation Trade Has A New Address: GenomicsSeekingAlpha
04:10AM
AI Is A Secular Growth UnicornSeekingAlpha
Jun-24-26
Jun-24-2610:46AM
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95Benzinga
Jun-18-26
Jun-18-2604:12PM
Twist Bioscience Files Prospectus For Offering Mixed Shelf; Terms UndisclosedBenzinga
01:01PM
Twist Bioscience: Huge Downside, With Little Hope Of ProfitsSeekingAlpha
Company

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Ownership
Total institutional ownership126.08%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue410377313245204132905425
Cost of Goods Sold Incl. D&A19718618015511981614732
Gross Profit213191133908452297-7
Selling, General and Administrative Excl. Other2732472181902131361038043
Research and Development72809110712069433620
Other Operating Expense704510-14-12301
Operating Income-139-136-221-217-235-153-140-109-71
Interest Expense000000111
Unusual Expense
—————————
Non-Operating Income (Expense)595913147-1131
Net Income Before Taxes-80-77-208-203-228-154-140-107-71
Income Taxes0111-10-2000
Consolidated Net Income-82-78-209-205-218-152-140-108-71
Net Income From Continuing Operations-82-78-209-205-218-152-140-108-71
Net Income-82-78-209-205-218-152-140-108-71
EPS (Recurring)-1.32-1.30-3.60-3.60-4.04-3.15-3.57-3.92-2.68
EPS (Basic, Before Extraordinaries)-1.32-1.30-3.60-3.60-4.04-3.15-3.57-3.92-2.68
EPS (Diluted)-1.33-1.30-3.60-3.60-4.04-3.15-3.57-3.92-2.68
EBITDA-57-52-177-174-212-144-132-100-64
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio15.284.488.374.719.3338.9032.9211.94—
Gross Margin51.9550.6642.4936.7341.1839.3932.2212.96-28.00
Operating Margin-33.90-36.07-70.61-88.57-115.20-115.91-155.56-201.85-284.00
Net Margin-20.00-20.69-66.77-83.67-106.86-115.15-155.56-200.00-284.00
Shares Outstanding626058575448392727
Market Capitalization6,2661,6882,6201,1551,9035,1352,963645—
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$114.69$89.10$63.52$37.94$12.35● Close Price0.00M2.09M4.17M6.26M8.34MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Finn Patrick JohnPresident and COOJul 23 '26Sale93.892,238210,133272,566Jul 27
Laponis AdamChief Financial OfficerJul 09 '26Sale94.332,399226,307110,276Jul 13
Leproust Emily M.Chief Executive OfficerJun 25 '26Sale95.0018,8801,793,600824,039Jun 26
Cho DennisSee RemarksJun 24 '26Sale89.7514,2051,274,899105,141Jun 26
Green PaulaSVP of Human ResourcesJun 22 '26Sale87.3229125,411120,414Jun 24
Cho DennisSee RemarksJun 22 '26Sale87.3234630,214119,346Jun 24
Leproust Emily M.Chief Executive OfficerJun 22 '26Sale87.321,688147,400842,919Jun 24
Green PaulaSVP of Human ResourcesJun 15 '26Option Exercise23.3326,137609,776146,842Jun 17
Green PaulaSVP of Human ResourcesJun 15 '26Sale81.6726,1372,134,488120,705Jun 17
WERNER ROBERT F.Chief Accounting OfficerJun 08 '26Sale69.201,35994,04646,827Jun 10
Cho DennisSee RemarksJun 08 '26Sale69.8440228,077119,692Jun 10
Green PaulaSVP of Human ResourcesJun 08 '26Sale69.8488461,742120,705Jun 10
Leproust Emily M.Chief Executive OfficerJun 08 '26Sale69.842,265158,197844,607Jun 10
Cho DennisSee RemarksMay 29 '26Sale69.7514,205990,799120,094Jun 02
Laponis AdamChief Financial OfficerMay 29 '26Sale70.004,000280,000112,675Jun 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.